{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:14:57Z","timestamp":1715577297085},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,12,24]],"date-time":"2008-12-24T00:00:00Z","timestamp":1230076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s11899-009-0004-7","type":"journal-article","created":{"date-parts":[[2008,12,23]],"date-time":"2008-12-23T06:33:28Z","timestamp":1230014008000},"page":"25-32","source":"Crossref","is-referenced-by-count":1,"title":["Do we know more about essential thrombocythemia because of JAK2V617F?"],"prefix":"10.1007","volume":"4","author":[{"given":"Claire","family":"Harrison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,24]]},"reference":[{"key":"4_CR1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C. James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144\u20131148.","journal-title":"Nature"},{"key":"4_CR2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"E.J. Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al.: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054\u20131061.","journal-title":"Lancet"},{"key":"4_CR3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"R.L. Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, et al.: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387\u2013397.","journal-title":"Cancer Cell"},{"key":"4_CR4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R. Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, et al.: A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779\u20131790.","journal-title":"N Engl J Med"},{"key":"4_CR5","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","volume":"280","author":"R. Zhao","year":"2005","unstructured":"Zhao R, Xing S, Li Z, et al.: Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005, 280:22788\u201322792.","journal-title":"J Biol Chem"},{"key":"4_CR6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","volume":"7","author":"R.L. Levine","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, Gilliland DG: Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007, 7:673\u2013683.","journal-title":"Nat Rev Cancer"},{"key":"4_CR7","doi-asserted-by":"crossref","unstructured":"Vainchenker W, Dusa A, Constantinescu SN: JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008 Jul 17 (Epub ahead of print).","DOI":"10.1016\/j.semcdb.2008.07.002"},{"key":"4_CR8","first-page":"719","volume":"91","author":"A.F. Remacha","year":"2006","unstructured":"Remacha AF, Nomdedeu JF, Puget G, et al.: Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic\/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis [letter]. Haematologica 2006, 91:719\u2013720.","journal-title":"Haematologica"},{"key":"4_CR9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"L.M. Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, et al.: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356:459\u2013468.","journal-title":"N Engl J Med"},{"key":"4_CR10","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","volume":"111","author":"D. Pietra","year":"2008","unstructured":"Pietra D, Li S, Brisci A, et al.: Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008, 111:1686\u20131689.","journal-title":"Blood"},{"key":"4_CR11","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"A.D. Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, et al.: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472\u20133476.","journal-title":"Blood"},{"key":"4_CR12","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y. Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, et al.: MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006, 3:e270.","journal-title":"PLoS Med"},{"key":"4_CR13","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","volume":"112","author":"A.M. Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, et al.: Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia. Blood 2008, 112:844\u2013847.","journal-title":"Blood"},{"key":"4_CR14","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.exphem.2007.08.010","volume":"35","author":"D.M. Williams","year":"2007","unstructured":"Williams DM, Kim AH, Rogers O, et al.: Phenotypic variations and new mutations in JAK2V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol 2007, 35:1641\u20131646.","journal-title":"Exp Hematol"},{"key":"4_CR15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","volume":"112","author":"P.A. Beer","year":"2008","unstructured":"Beer PA, Campbell PJ, Scott LM, et al.: MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008, 112:141\u2013149.","journal-title":"Blood"},{"key":"4_CR16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","volume":"6","author":"W. Dameshek","year":"1951","unstructured":"Dameshek W: Some speculations on the myeloproliferative syndromes. Blood 1951, 6:372\u2013375.","journal-title":"Blood"},{"key":"4_CR17","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A. Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A, et al.: Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092\u20131097.","journal-title":"Blood"},{"key":"4_CR18","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"P.J. Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G, et al.: Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2V617F mutation status: a prospective study. Lancet 2005, 366:1945\u20131953.","journal-title":"Lancet"},{"key":"4_CR19","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","volume":"107","author":"G. Wernig","year":"2006","unstructured":"Wernig G, Mercher T, Okabe R, et al.: Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006, 107:4274\u20134281.","journal-title":"Blood"},{"key":"4_CR20","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1371\/journal.pone.0000018","volume":"1","author":"V.M. Zaleskas","year":"2006","unstructured":"Zaleskas VM, Krause DS, Lazarides K, et al.: Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2V617F. PLoS ONE 2006, 1:e18.","journal-title":"PLoS ONE"},{"key":"4_CR21","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1182\/blood-2007-06-095703","volume":"111","author":"A. Pardanani","year":"2008","unstructured":"Pardanani A, Fridley BL, Lasho TL, et al.: Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008, 111:2785\u20132789.","journal-title":"Blood"},{"key":"4_CR22","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","volume":"108","author":"L.M. Scott","year":"2006","unstructured":"Scott LM, Scott MA, Campbell PJ, Green AR: Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006, 108:2435\u20132437.","journal-title":"Blood"},{"key":"4_CR23","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2008-01-134114","volume":"112","author":"I. Plo","year":"2008","unstructured":"Plo I, Nakatake M, Malivert L, et al.: JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008, 112:1402\u20131412.","journal-title":"Blood"},{"key":"4_CR24","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","volume":"22","author":"A.M. Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, et al.: Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008, 22:1299\u20131307.","journal-title":"Leukemia"},{"key":"4_CR25","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood-2006-03-008805","volume":"108","author":"A.R. Moliterno","year":"2006","unstructured":"Moliterno AR, Williams DM, Rogers O, Spivak JL: Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2V617F and Mpl expression. Blood 2006, 108:3913\u20133915.","journal-title":"Blood"},{"key":"4_CR26","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","volume":"107","author":"F. Passamonti","year":"2006","unstructured":"Passamonti F, Rumi E, Pietra D, et al.: Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006, 107:3676\u20133682.","journal-title":"Blood"},{"key":"4_CR27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","volume":"106","author":"A. Tefferi","year":"2006","unstructured":"Tefferi A, Lasho TL, Schwager SM, et al.: The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006, 106:631\u2013635.","journal-title":"Cancer"},{"key":"4_CR28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2007.06755.x","volume":"139","author":"K. Toyama","year":"2007","unstructured":"Toyama K, Karasawa M, Yamane A, et al.: JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. Br J Haematol 2007, 139:64\u201369.","journal-title":"Br J Haematol"},{"key":"4_CR29","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood.V89.1.128","volume":"89","author":"N. El-Kassar","year":"1997","unstructured":"El-Kassar N, Hetet G, Briere J, Grandchamp B: Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood 1997, 89:128\u2013134.","journal-title":"Blood"},{"key":"4_CR30","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","volume":"108","author":"R. Kralovics","year":"2006","unstructured":"Kralovics R, Teo SS, Li S, et al.: Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006, 108:1377\u20131380.","journal-title":"Blood"},{"key":"4_CR31","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2141.2006.06348.x","volume":"135","author":"T.L. Lasho","year":"2006","unstructured":"Lasho TL, Pardanani A, McClure RF, et al.: Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 2006, 135:683\u2013687.","journal-title":"Br J Haematol"},{"key":"4_CR32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2006.11.012","volume":"35","author":"R.H. Nussenzveig","year":"2007","unstructured":"Nussenzveig RH, Swierczek SI, Jelinek J, et al.: Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007, 35:32\u201338.","journal-title":"Exp Hematol"},{"key":"4_CR33","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/cncr.22240","volume":"107","author":"E. Rumi","year":"2006","unstructured":"Rumi E, Passamonti F, Pietra D, et al.: JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 2006, 107:2206\u20132211.","journal-title":"Cancer"},{"key":"4_CR34","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","volume":"108","author":"P.J. Campbell","year":"2006","unstructured":"Campbell PJ, Baxter EJ, Beer PA, et al.: Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006, 108:3548\u20133555.","journal-title":"Blood"},{"key":"4_CR35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","volume":"110","author":"A. Theocharides","year":"2007","unstructured":"Theocharides A, Boissinot M, Girodon F, et al.: Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007, 110:375\u2013379.","journal-title":"Blood"},{"key":"4_CR36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","volume":"111","author":"B.S. Wilkins","year":"2008","unstructured":"Wilkins BS, Erber WN, Bareford D, et al.: Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008, 111:60\u201370.","journal-title":"Blood"},{"key":"4_CR37","doi-asserted-by":"crossref","unstructured":"Tefferi A: Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006, 240\u2013245.","DOI":"10.1182\/asheducation-2006.1.240"},{"key":"4_CR38","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.beha.2005.07.004","volume":"19","author":"C.N. Harrison","year":"2006","unstructured":"Harrison CN, Green AR: Essential thrombocythaemia. Best Pract Res Clin Haematol 2006, 19:439\u2013453.","journal-title":"Best Pract Res Clin Haematol"},{"key":"4_CR39","first-page":"215","volume":"89","author":"T. Barbui","year":"2004","unstructured":"Barbui T, Barosi G, Grossi A, et al.: Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004, 89:215\u2013232.","journal-title":"Haematologica"},{"key":"4_CR40","doi-asserted-by":"crossref","unstructured":"Dahabreh IJ, Zoi K, Giannouli S, et al.: Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2008 Jul 14 (Epub ahead of print).","DOI":"10.1016\/j.leukres.2008.06.006"},{"key":"4_CR41","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","volume":"110","author":"A.M. Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, et al.: Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, 110:840\u2013846.","journal-title":"Blood"},{"key":"4_CR42","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2008-04-153783","volume":"112","author":"A. Carobbio","year":"2008","unstructured":"Carobbio A, Finazzi G, Antonioli E, et al.: Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008, 112:3135\u20133137.","journal-title":"Blood"},{"key":"4_CR43","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","volume":"110","author":"F. Passamonti","year":"2007","unstructured":"Passamonti F, Randi ML, Rumi E, et al.: Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood 2007, 110:485\u2013489.","journal-title":"Blood"},{"key":"4_CR44","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1056\/NEJMc071528","volume":"357","author":"E. Mercier","year":"2007","unstructured":"Mercier E, Lissalde-Lavigne G, Gris JC: JAK2V617F mutation in unexplained loss of first pregnancy [letter]. N Engl J Med 2007, 357:1984\u20131985.","journal-title":"N Engl J Med"},{"key":"4_CR45","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1182\/blood-2007-06-094276","volume":"110","author":"L. Teofili","year":"2007","unstructured":"Teofili L, Giona F, Martini M, et al.: The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 2007, 110:3384\u20133386.","journal-title":"Blood"},{"key":"4_CR46","first-page":"558","volume":"110","author":"S. Verstovsek","year":"2007","unstructured":"Verstovsek S, Kantarjian H, Pardanani A, et al.: INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I\/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera\/essential thrombocythemia myelofibrosis (post-PV\/ET MF) [abstract 558]. Blood (ASH Annual Meeting Abstracts) 2007, 110:558.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"4_CR47","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"J.J. Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S, et al.: Pegylated interferon- alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008, 112:3065\u20133072.","journal-title":"Blood"},{"key":"4_CR48","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3324\/haematol.12801","volume":"93","author":"A. Ricksten","year":"2008","unstructured":"Ricksten A, Palmqvist L, Johansson P, Andreasson B: Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 2008, 93:1260\u20131261.","journal-title":"Haematologica"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0004-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-009-0004-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0004-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T02:03:34Z","timestamp":1589421814000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-009-0004-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,24]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s11899-009-0004-7","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,24]]}}}